MODY: History, genetics, pathophysiology, and clinical decision making

Diabetes Care

Volumn 34, Issue 8, 2011, Pages 1878-1884

  Fajans, Stefan S ^a   Bell, Graeme I ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; BIOLOGICAL MARKER; GLUCOKINASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA;

ADENOSINE DEAMINASE GENE; BODY WEIGHT; CLINICAL DECISION MAKING; CLINICAL FEATURE; DISEASE COURSE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GLUCOKINASE GENE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA GENE; HUMAN; HYPOGLYCEMIA; INSULIN PROMOTER FACTOR 1 GENE; INSULIN RELEASE; MACROSOMIA; MATURITY ONSET DIABETES MELLITUS; MUTATIONAL ANALYSIS; MUTATOR GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHENOTYPIC VARIATION; REVIEW; DECISION MAKING; GENETICS; UNITED STATES;

BODY WEIGHT; DECISION MAKING; DIABETES MELLITUS, TYPE 2; HUMANS; ILLINOIS; MICHIGAN;

EID: 80955170054     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0035     Document Type: Review

References (60)

1. Fajans SS, Conn JW. An approach to the prediction of diabetes mellitus by modification of the glucose tolerance test with cortisone. Diabetes 1954;3:296-302; discussion, 302-304
2. Fajans SS, Conn JW. The early recognition of diabetes mellitus. Ann N Y Acad Sci 1959;82:208-218
3. Fajans SS, Conn JW. Tolbutamide-induced improvement in carbohydrate tolerance of young people with mild diabetes mellitus. Diabetes 1960;9:83-88
4. Fajans SS, Conn JW. The use of tolbutamide in the treatment of young people with mild diabetes mellitus - a progress report. Diabetes 1962;11:123-126
5. Fajans SS, Brown MB. Administration of sulfonylureas can increase glucose-induced insulin secretion for decades in patients with maturity-onset diabetes of the young. Diabetes Care 1993;16:1254-1261 (Pubitemid 23259866)
6. Fajans SS, Cloutier MC, Crowther RL. The Banting Memorial Lecture 1978. Clinical and etiologic heterogeneity of idiopathic diabetes mellitus. Diabetes 1978;27:1112-1125 (Pubitemid 9086671)
7. Fajans SS. Scope and heterogeneous nature of MODY. Diabetes Care 1990;13:49-64 (Pubitemid 20024729)
8. Fajans SS, Bell GI, Bowden DW. MODY: a model for the study of the molecular genetics of NIDDM. J Lab Clin Med 1992;119:206-210
9. Fajans SS, Bell GI, Bowden DW, Halter JB, Polonsky KS. Maturity-onset diabetes of the young. Life Sci 1994;55:413-422 (Pubitemid 24227618)
10. Fajans SS, Conn JW. Prediabetes, subclinical diabetes and latent clinical diabetes: interpretation, diagnosis and treatment. In On the Nature and Treatment of Diabetes. New York, NY, Excerpta Medica, 1965, p. 641-656 (Int. Cong. Ser., no. 84)
11. Neel J, Fajans SS, Conn JW, Davidson RT. Diabetes mellitus. In Genetics and the Epidemiology of Chronic Disease. Washington, DC, U.S. Public Health Service, 1965, p. 105-132 (publ. no. 1163)
12. Tattersall RB. Mild familial diabetes with dominant inheritance. Q J Med 1974;43:339-357
13. Tattersall RB, Mansell PI. Maturity onsettype diabetes of the young (MODY): one condition or many? Diabet Med 1991;8:402-410
14. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenileonset and maturity-onset type diabetes of young people. Diabetes 1975;24:44-53
15. Cammidge PJ. Diabetes mellitus and heredity. BMJ 1928;2:738-741
16. Møller AM, Dalgaard LT, Pociot F, Nerup J, Hansen T, Pedersen O. Mutations in the hepatocyte nuclear factor-1a gene in Caucasian families originally classified as having type I diabetes. Diabetologia 1998;41:1528-1531 (Pubitemid 28551626)
17. Fajans SS, Floyd JC Jr, Tattersall RB, Williamson JR, Pek S, Taylor CI. The various faces of diabetes in the young: changing concepts. Arch Intern Med 1976;136:194-202
18. Fajans SS. MODY - a model for understanding the pathogeneses and natural history of type II diabetes. Horm Metab Res 1987;19:591-599 (Pubitemid 18014139)
19. Fajans SS, Floyd JC Jr, Pek S, Conn JW. The course of asymptomatic diabetes in young people, as determined by levels of blood glucose and plasma insulin. Trans Assoc Am Physicians 1969;82:211-224
20. Fajans SS. Heterogeneity of insulin secretion in type II diabetes. Diabetes Metab Rev 1986;2:347-361 (Pubitemid 16009514)
21. Andreone T, Fajans SS, Rotwein P, Skolnick M, Permutt MA. Insulin gene analysis in a family with maturity-onset diabetes of the young. Diabetes 1985;34:108-114 (Pubitemid 15155957)
22. Elbein SC, Borecki I, Corsetti L, et al. Linkage analysis of the human insulin receptor gene and maturity onset diabetes of the young. Diabetologia 1987;30:641-647 (Pubitemid 17139974)
23. Vinik AJ, Cox NJ, Xiang K, Fajans SS, Bell GI. Linkage studies of maturity onset diabetes of the young - R.W. pedigree. Diabetologia 1988;31:778
24. Bell GI, Xiang K, Newman MV, et al. Gene for non-insulin-dependent diabetes mellitus (maturity-onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome 20q. Proc Natl Acad Sci USA 1991;88:1484-1488 (Pubitemid 21916249)
25. Bowden DW, Gravius TC, Akots G, Fajans SS. Identification of genetic markers flanking the locus for maturity-onset diabetes of the young on human chromosome 20. Diabetes 1992;41:88-92
26. Yamagata K, Furuta H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4α gene in maturity-onset diabetes of the young (MODY1). Nature 1996;384:458-460 (Pubitemid 26414661)
27. Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1α gene in maturity-onset diabetes of the young (MODY3). Nature 1996;384:455-458 (Pubitemid 26414660)
28. Froguel P, Vaxillaire M, Sun F, et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 1992;356:162-164
29. Hattersley AT, Turner RC, Permutt MA, et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet 1992;339:1307-1310
30. Vionnet N, Stoffel M, Takeda J, et al. Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus. Nature 1992;356:721-722
31. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997;17:138-139
32. Fajans SS, Bell GI, Paz VP, et al. Obesity and hyperinsulinemia in a family with pancreatic agenesis and MODY caused by the IPF1mutation Pro63fsX60. Transl Res 2010;156:7-14
33. Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 1997;17:384-385
34. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are wemissing? Diabetologia 2010;53:2504-2508
35. Fajans SS, Bell GI.Maturity-onset diabetes of the young: a model for genetic studies of diabetes mellitus. In Diabetes Mellitus: A Fundamental and Clinical Text. 2nd ed. LeRoith D, Taylor SF, Olefsky JM, Eds. Philadelphia, PA, J.P. Lippincott Company, 2000, p. 691-705
36. Herman WH, Fajans SS, Ortiz FJ, et al. Abnormal insulin secretion, not insulin resistance, is the genetic or primary defect of MODY in the RW pedigree. Diabetes 1994;43:40-46
37. Byrne MM, Sturis J, Fajans SS, et al. Altered insulin secretory responses to glucose in subjects with a mutation in the MODY1 gene on chromosome 20. Diabetes 1995;44:699-704
38. Byrne MM, Sturis J, Clément K, et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 1994;93:1120-1130 (Pubitemid 24087166)
39. Byrne MM, Sturis J, Menzel S, et al. Altered insulin secretory responses to glucose in diabetic and nondiabetic subjects with mutations in the diabetes susceptibility gene MODY3 on chromosome 12. Diabetes 1996;45:1503-1510 (Pubitemid 26357541)
40. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001;345:971-980
41. Fajans SS, Floyd JC Jr, Knopf RF, Conn FW. Effect of amino acids and proteins on insulin secretion in man. Recent Prog Horm Res 1967;23:617-662
42. Herman WH, Fajans SS, Smith MJ, Polonsky KS, Bell GI,Halter JB. Diminished insulin and glucagon secretory responses to arginine in nondiabetic subjects with a mutation in the hepatocyte nuclear factor-4α/MODY1 gene. Diabetes 1997;46:1749-1754 (Pubitemid 27456406)
43. Ilag LL, Tabaei BE, Herman WH, et al. Reduced pancreatic polypeptide response to hypoglycemia and amylin response to arginine in subjects with amutation in the HNF-4α/MODY1 gene. Diabetes 2000;49:961-968 (Pubitemid 30349418)
44. Lehto M, Bitzén PO, Isomaa B, et al. Mutation in the HNF-4alpha gene affects insulin secretion and triglyceride metabolism. Diabetes 1999;48:423-425 (Pubitemid 29061121)
45. Shih DQ, Dansky HM, Fleisher M, Assmann G, Fajans SS, Stoffel M. Genotype/phenotype relationships in HNF-4α/MODY1: haploinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein (CIII), lipoprotein(a), and triglyceride levels. Diabetes 2000;49:832-837 (Pubitemid 30340001)
46. Richter S, Shih DQ, Pearson ER, et al. Regulation of apolipoprotein M gene expression by MODY3 gene hepatocyte nuclear factor-1α: haploinsufficiency is associated with reduced serum apolipoprotein M levels. Diabetes 2003;52:2989-2995 (Pubitemid 37466870)
47. Owen KR, Thanabalasingham G, James TJ, et al. Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations. Diabetes Care 2010;33:1919-1924
48. Fajans SS, Bell GI. Phenotypic heterogeneity between different mutations of MODY subtypes and within MODY pedigrees. Diabetologia 2006;49:1106-1108
49. Cuesta-Muñoz AL, Tuomi T, Cobo- Vuilleumier N, et al. Clinical heterogeneity in monogenic diabetes caused by mutations in the glucokinase gene (GCKMODY). Diabetes Care 2010;33:290-292
50. Pearson ER, Boj SF, Steele AM, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med 2007;4:e118
51. Fajans SS, Bell GI. Macrosomia and neonatal hypoglycaemia in RW pedigree subjects with a mutation (Q268X) in the gene encoding hepatocyte nuclear factor 4α (HNF4A). Diabetologia 2007;50:2600-2601 (Pubitemid 350060650)
52. Voight BF, Scott LJ, Steinthorsdottir V, et al.; MAGIC investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42:579-589
53. Jafar-Mohammadi B, Groves CJ, Gjesing AP, et al.; DIAGRAM Consortium. A role for coding functional variants in HNF4A in type 2 diabetes susceptibility. Diabetologia 2011;54:111-119
54. Fajans SS, Herman WH, Oral EA. Insufficient sensitivity of hemoglobin A(1C) determination in diagnosis or screening of early diabetic states.Metabolism2011;60:86-91
55. Lorini R, Klersy C, d'Annunzio G, et al.; Italian Society of Pediatric Endocrinology and Diabetology (ISPED) Study Group. Maturity-onset diabetes of the young in children with incidental hyperglycemia: amulticenter Italian study of 172 families. Diabetes Care 2009;32:1864-1866
56. Tuomi T, Honkanen EH, Isomaa B, Sarelin L, Groop LC. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. Diabetes Care 2006;29:189-194 (Pubitemid 44121080)
57. Fujimoto K, Ford EL, Tran H, et al. Loss of Nix in Pdx1-deficient mice prevents apoptotic and necrotic b cell death and diabetes. J Clin Invest 2010;120:4031-4039
58. American Diabetes Association. Standards ofmedical care in diabetes - 2010. Diabetes Care 2010;33:S11-S61
59. Hattersley A, Bruining J, Shield J,Njolstad P, Donaghue KC. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2009;10(Suppl. 12):33-42
60. Ellard S, Bellanné-Chantelot C, Hattersley AT; European Molecular Genetics Quality Network (EMQN) MODY group. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008;51:546-553